NO982350L - Stamcellefaktor - Google Patents

Stamcellefaktor

Info

Publication number
NO982350L
NO982350L NO982350A NO982350A NO982350L NO 982350 L NO982350 L NO 982350L NO 982350 A NO982350 A NO 982350A NO 982350 A NO982350 A NO 982350A NO 982350 L NO982350 L NO 982350L
Authority
NO
Norway
Prior art keywords
stem cell
cell factor
factor
stem
cell
Prior art date
Application number
NO982350A
Other languages
English (en)
Other versions
NO316022B1 (no
NO982350D0 (no
Inventor
Krisztina M Zsebo
Robert A Bosselman
Sidney Vaughn Suggs
Francis Hall Martin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO982350D0 publication Critical patent/NO982350D0/no
Publication of NO982350L publication Critical patent/NO982350L/no
Publication of NO316022B1 publication Critical patent/NO316022B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
NO19982350A 1989-10-16 1998-05-22 Polypeptid som har ±n eller flere av de biologiske aktiviteter til naturligforekommende stamcellefaktor, inkludert hematopoetisk aktivitet,antistoff sombinder det, samt fremgangsmåte for fremstilling av polypeptidet NO316022B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42238389A 1989-10-16 1989-10-16
US53719890A 1990-06-11 1990-06-11
US57361690A 1990-08-24 1990-08-24
PCT/US1990/005548 WO1991005795A1 (en) 1989-10-16 1990-09-28 Stem cell factor

Publications (3)

Publication Number Publication Date
NO982350D0 NO982350D0 (no) 1998-05-22
NO982350L true NO982350L (no) 1998-05-22
NO316022B1 NO316022B1 (no) 2003-12-01

Family

ID=27411345

Family Applications (3)

Application Number Title Priority Date Filing Date
NO912321A NO303830B1 (no) 1989-10-16 1991-06-14 FremgangsmÕte for fremstilling av et polypeptid med den biologiske hematopoeseaktivitet Õ stimulere vekst av tidlige hematopoeseforl°perceller
NO964445A NO303831B1 (no) 1989-10-16 1996-10-18 Isolert DNA-sekvens, vektor, vertscelle, polypeptid og anvendelse in vitro av polypeptidet ved en fremgangsmÕte for transfeksjon av hematopoeseceller med eksogen DNA
NO19982350A NO316022B1 (no) 1989-10-16 1998-05-22 Polypeptid som har ±n eller flere av de biologiske aktiviteter til naturligforekommende stamcellefaktor, inkludert hematopoetisk aktivitet,antistoff sombinder det, samt fremgangsmåte for fremstilling av polypeptidet

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO912321A NO303830B1 (no) 1989-10-16 1991-06-14 FremgangsmÕte for fremstilling av et polypeptid med den biologiske hematopoeseaktivitet Õ stimulere vekst av tidlige hematopoeseforl°perceller
NO964445A NO303831B1 (no) 1989-10-16 1996-10-18 Isolert DNA-sekvens, vektor, vertscelle, polypeptid og anvendelse in vitro av polypeptidet ved en fremgangsmÕte for transfeksjon av hematopoeseceller med eksogen DNA

Country Status (17)

Country Link
US (1) US20080305074A1 (no)
JP (1) JP2657113B2 (no)
KR (2) KR100193050B1 (no)
AU (3) AU6541090A (no)
CA (8) CA2267668C (no)
ES (2) ES2314999T3 (no)
FI (2) FI108140B (no)
GE (2) GEP20033145B (no)
HU (2) HUT62011A (no)
IE (2) IE903562A1 (no)
IL (4) IL95905A (no)
LV (1) LV10462B (no)
NO (3) NO303830B1 (no)
NZ (1) NZ235571A (no)
PT (1) PT95524B (no)
RU (1) RU2212411C2 (no)
WO (1) WO1991005795A1 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107642A0 (en) * 1992-11-20 1994-02-27 Amgen Inc Progenitor b cell stimulating factor
US6012450A (en) * 1993-01-29 2000-01-11 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
ATE196775T1 (de) * 1993-05-19 2000-10-15 Schering Corp Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5459031A (en) * 1993-11-05 1995-10-17 Amgen Inc. Methods for controlling sialic acid derivatives in recombinant glycoproteins
JPH07165602A (ja) * 1993-12-16 1995-06-27 Kirin Brewery Co Ltd 放射線障害防護剤
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US5525708A (en) * 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand
EP0817655B1 (en) * 1995-03-31 2004-05-19 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
US5824789A (en) * 1995-06-07 1998-10-20 Systemix, Inc. Human growth factors, nucleotide sequence encoding growth factors, and method of use thereof
GB9515839D0 (en) * 1995-08-02 1995-10-04 Q One Biotech Ltd Feline stem cell factor
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5885962A (en) * 1996-04-05 1999-03-23 Amgen Inc. Stem cell factor analog compositions and method
US5969105A (en) * 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
CA2301979A1 (en) * 1997-09-10 1999-03-18 Uab Research Foundation Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
JP5099951B2 (ja) 1999-11-12 2012-12-19 バクスター・インターナショナル・インコーポレイテッド 副作用が減少されたヘモグロビン組成物
EP3020804A1 (en) 2000-07-06 2016-05-18 Sarepta Therapeutics, Inc. Transforming growth factor beta (tgf- ) blocking agent-treated stem cell composition and method
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
AU2004313245B2 (en) 2003-12-30 2011-04-14 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
CA2581769C (en) 2004-09-28 2014-03-11 Genexel-Sein, Inc. Methods of using chimeric coiled-coil molecule
US20060153799A1 (en) 2004-11-05 2006-07-13 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
WO2007098548A1 (en) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
EP3241558B1 (en) 2010-09-28 2021-03-03 Aegerion Pharmaceuticals, Inc. Highly soluble leptins
KR102119187B1 (ko) * 2011-01-10 2020-06-08 더 리젠츠 오브 더 유니버시티 오브 미시간 줄기 세포 인자 억제제
AU2014212009B2 (en) * 2013-02-04 2020-01-30 Roger Williams Medical Center Methods and compositions for treating gastrointestinal stromal tumor (GIST)
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
CN109661462A (zh) * 2016-07-19 2019-04-19 阿塞尔塔有限公司 用于在悬浮下培养多能性干细胞的培养基
TW202124434A (zh) * 2019-09-16 2021-07-01 美商歐普西迪歐有限責任公司 抗-幹細胞因子抗體及其使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2245815A1 (de) * 1972-09-19 1974-03-28 Bodenseewerk Perkin Elmer Co Verfahren und vorrichtung zur identifizierung und auswertung von peaks in chromatogrammen
JPS6030291B2 (ja) * 1978-03-20 1985-07-16 森永乳業株式会社 人顆粒球の分化増殖を促進するｈｇｉ糖蛋白質、ｈｇｉ糖蛋白質の製造法及びｈｇｉ糖蛋白質を含有する白血球減少症治療剤
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4353242A (en) * 1980-12-16 1982-10-12 University Of Utah Research Foundation Multichannel detection and resolution of chromatographic peaks
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
US4722998A (en) * 1982-10-20 1988-02-02 Dana Farber Cancer Institute Method of producing lymphocyte growth factors
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
US4714680B1 (en) * 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH0753667B2 (ja) * 1985-08-09 1995-06-07 新技術開発事業団 骨髄移植療法補助剤
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS62223126A (ja) * 1986-03-25 1987-10-01 Sankyo Co Ltd 血液幹細胞成長因子
US4721096A (en) * 1986-04-18 1988-01-26 Marrow-Tech Incorporated Process for replicating bone marrow in vitro and using the same
US4879227A (en) * 1986-05-06 1989-11-07 Genetics Institute, Inc. Production of a recombinant human colony stimulating factor
US4877729A (en) * 1986-07-14 1989-10-31 Genetics Institute, Inc. Recombinant DNA encoding novel family of primate hematopoietic growth factors
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4808611A (en) * 1986-07-30 1989-02-28 Immunex Corporation Use of interleukin-1 to induce development of multipotent hemopoietic cell populations
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
DE3810094A1 (de) * 1988-03-25 1989-10-05 Agfa Gevaert Ag Roentgenaufnahmefolie mit einer stimulierbaren phosphorschicht und geraet zu deren behandlung und auswertung
US5087570A (en) * 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition
US4874325A (en) * 1988-09-23 1989-10-17 General Motors Corporation Electrical connector with interface seal
US5119315A (en) * 1989-04-28 1992-06-02 Amoco Corporation Method of correlating a record of sample data with a record of reference data
US6248319B1 (en) * 1989-10-16 2001-06-19 Krisztina M. Zsebo Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
US6852313B1 (en) * 1989-10-16 2005-02-08 Amgen Inc. Method of stimulating growth of melanocyte cells by administering stem cell factor
US5767074A (en) * 1990-08-27 1998-06-16 Sloan-Kettering Institute For Cancer Research Compositions of soluble C-kit ligand and hematopoietic factors
US20030125519A1 (en) * 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US5121337A (en) * 1990-10-15 1992-06-09 Exxon Research And Engineering Company Method for correcting spectral data for data due to the spectral measurement process itself and estimating unknown property and/or composition data of a sample using such method
WO1992017505A1 (en) * 1991-04-05 1992-10-15 Board Of Regents Of The University Of Washington Monoclonal antibodies to stem cell factor receptors
US5545533A (en) * 1991-05-25 1996-08-13 Boehringer Mannheim Gmbh Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US5599703A (en) * 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
JPH07165602A (ja) * 1993-12-16 1995-06-27 Kirin Brewery Co Ltd 放射線障害防護剤
US5610056A (en) * 1994-11-16 1997-03-11 Amgen Inc. Use of stem cell factor interleukin-6 and soluble interleukin-6 receptor to induce the development of hematopoietic stem cells
US5911988A (en) * 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
DE19600589C1 (de) * 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2

Also Published As

Publication number Publication date
HU220234B (hu) 2001-11-28
IE20010893A1 (en) 2003-03-05
IL127924A (en) 2006-12-31
GEP20033145B (en) 2003-12-25
KR100210241B1 (en) 1999-07-15
AU712721B2 (en) 1999-11-11
NO964445D0 (no) 1996-10-18
CA2267668A1 (en) 1991-04-17
LV10462A (lv) 1995-02-20
ES2147720T3 (es) 2000-10-01
CA2026915C (en) 2006-11-28
CA2267626A1 (en) 1991-04-17
CA2026915A1 (en) 1991-04-17
CA2267658A1 (en) 1991-04-17
NO912321L (no) 1991-08-16
KR100193050B1 (ko) 1999-06-15
PT95524B (pt) 1997-08-29
FI108140B (fi) 2001-11-30
NO964445L (no) 1996-10-18
AU1771297A (en) 1997-06-19
CA2267643A1 (en) 1991-04-17
CA2267670C (en) 2005-01-11
PT95524A (pt) 1991-09-13
JPH04502628A (ja) 1992-05-14
KR920701238A (ko) 1992-08-11
CA2267651C (en) 2008-01-29
NZ235571A (en) 1997-06-24
LV10462B (en) 1996-04-20
FI120312B (fi) 2009-09-15
US20080305074A1 (en) 2008-12-11
FI20011804A (fi) 2001-09-13
NO912321D0 (no) 1991-06-14
CA2267668C (en) 2008-02-19
HU912386D0 (en) 1991-12-30
GEP20002145B (en) 2000-06-25
JP2657113B2 (ja) 1997-09-24
CA2267671A1 (en) 1991-04-17
AU674570B2 (en) 1997-01-02
CA2267651A1 (en) 1991-04-17
IL95905A (en) 2002-02-10
AU6541090A (en) 1991-05-16
IL170681A (en) 2010-04-15
RU2212411C2 (ru) 2003-09-20
ES2314999T3 (es) 2009-03-16
NO303831B1 (no) 1998-09-07
IE903562A1 (en) 1991-04-24
IL95905A0 (no) 1991-07-18
CA2267671C (en) 2008-12-02
NO303830B1 (no) 1998-09-07
WO1991005795A1 (en) 1991-05-02
NO316022B1 (no) 2003-12-01
AU6060394A (en) 1994-07-07
IL127924A0 (en) 2000-02-17
CA2267670A1 (en) 1991-04-17
HUT62011A (en) 1993-03-29
FI912857A0 (fi) 1991-06-13
NO982350D0 (no) 1998-05-22

Similar Documents

Publication Publication Date Title
NO982350L (no) Stamcellefaktor
IT9067025A0 (it) Valvola
DK38790A (da) Stilladsmodul
DK664989D0 (da) Mikrodrivapparat
FR2634652B1 (fr) Valve respiratoire asservissable
NO173645C (no) Maaleventil
DE69032498D1 (de) Zellenvermittlungseinrichtung
FI892628A0 (fi) Nikkelin uutosprosessi
NO168145C (no) Celle
DE69024768D1 (de) Ventilanordnung
BR8907717A (pt) Valvula
FI87937C (fi) Elektrolytisk cell
FI893497A (fi) Elektrokemisk cell med dubbelverkande elektrod.
NO914199D0 (no) Ventiler
DK261990D0 (da) Procalcitoninpeptider
DK119691D0 (da) Loeftesele
ATA296888A (de) Labyrinthanordnung
NO169999C (no) Langrennsski
IT1224155B (it) Irdomo piramidale
ZA907921B (en) Stem cell factor
IT8884606A0 (it) Struttura di valvola
SE8904002D0 (sv) Ventilkonstruktion
SE8903929D0 (sv) Ventilkonstruktion
PT87351A (pt) Central solar
FR2644868B1 (fr) Soupape autostable

Legal Events

Date Code Title Description
MK1K Patent expired